Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edit Dulka

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Orvosi Hetilap|June 23, 2004
[Bronchoscopic specimen collection, role of the protected specimen brush in lower respiratory tract infections]Edit Dulka, Eva Bán, János Strausz
Journal of Translational Medicine|November 20, 2024
Gut metatranscriptomics based de novo assembly reveals microbial signatures predicting immunotherapy outcomes in non-small cell lung cancerDavid Dora, Peter Kiraly, Csenge Somodi, et al.
Orvosi Hetilap|September 16, 2004
[Our experience using autofluorescence bronchoscopy]Gábor Kovács, Edit Dulka, Zsuzsanna Márk, et al.
Frontiers in Cellular and Infection Microbiology|December 5, 2024
Metabolic pathways from the gut metatranscriptome are associated with COPD and respiratory function in lung cancer patientsDavid Dora, Peter Revisnyei, Anna Mihucz, et al.
Cancers|October 28, 2023
Computed Tomography-Based Quantitative Texture Analysis and Gut Microbial Community Signatures Predict Survival in Non-Small Cell Lung CancerDavid Dora, Glen J Weiss, Zsolt Megyesfalvi, et al.
Frontiers in Immunology|April 29, 2025
Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patientsDavid Dora, Peter Revisnyei, Alija Pasic, et al.
Oncoimmunology|May 17, 2023
Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 statusDavid Dora, Balazs Ligeti, Tamas Kovacs, et al.
The ISME Journal|May 18, 2021
Distinct composition and metabolic functions of human gut microbiota are associated with cachexia in lung cancer patientsYueqiong Ni, Zoltan Lohinai, Yoshitaro Heshiki, et al.
Plos One|November 18, 2021
Gut microbiome functionality might be associated with exercise tolerance and recurrence of resected early-stage lung cancer patientsAndrea Marfil-Sánchez, Bastian Seelbinder, Yueqiong Ni, et al.
Nature Communications|May 10, 2023
Candida expansion in the gut of lung cancer patients associates with an ecological signature that supports growth under dysbiotic conditionsBastian Seelbinder, Zoltan Lohinai, Ruben Vazquez-Uribe, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Orvosi Hetilap|June 23, 2004
[Bronchoscopic specimen collection, role of the protected specimen brush in lower respiratory tract infections]Edit Dulka, Eva Bán, János Strausz
Journal of Translational Medicine|November 20, 2024
Gut metatranscriptomics based de novo assembly reveals microbial signatures predicting immunotherapy outcomes in non-small cell lung cancerDavid Dora, Peter Kiraly, Csenge Somodi, et al.
Orvosi Hetilap|September 16, 2004
[Our experience using autofluorescence bronchoscopy]Gábor Kovács, Edit Dulka, Zsuzsanna Márk, et al.
Frontiers in Cellular and Infection Microbiology|December 5, 2024
Metabolic pathways from the gut metatranscriptome are associated with COPD and respiratory function in lung cancer patientsDavid Dora, Peter Revisnyei, Anna Mihucz, et al.
Cancers|October 28, 2023
Computed Tomography-Based Quantitative Texture Analysis and Gut Microbial Community Signatures Predict Survival in Non-Small Cell Lung CancerDavid Dora, Glen J Weiss, Zsolt Megyesfalvi, et al.
Frontiers in Immunology|April 29, 2025
Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patientsDavid Dora, Peter Revisnyei, Alija Pasic, et al.
Oncoimmunology|May 17, 2023
Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 statusDavid Dora, Balazs Ligeti, Tamas Kovacs, et al.
The ISME Journal|May 18, 2021
Distinct composition and metabolic functions of human gut microbiota are associated with cachexia in lung cancer patientsYueqiong Ni, Zoltan Lohinai, Yoshitaro Heshiki, et al.
Plos One|November 18, 2021
Gut microbiome functionality might be associated with exercise tolerance and recurrence of resected early-stage lung cancer patientsAndrea Marfil-Sánchez, Bastian Seelbinder, Yueqiong Ni, et al.
Nature Communications|May 10, 2023
Candida expansion in the gut of lung cancer patients associates with an ecological signature that supports growth under dysbiotic conditionsBastian Seelbinder, Zoltan Lohinai, Ruben Vazquez-Uribe, et al.
Pageof 1